Transcatheter aortic valve implantation (TAVR) is rapidly evolving to become the standard of care for all types of aortic stenosis (AS) patients, as opposed to open-heart surgery. The emergence of new commercial TAVR devices, as well as technological advancements in AS diagnosis and procedural planning, combat post-TAVR complications while also posing new challenges with patient selection and optimal timing of valve replacement. Computational modeling is a powerful tool that may help streamline solutions for heart teams when faced with these complexities.

Hypertensive disorders of pregnancy portend future cardiovascular risk and warrant implementation of evidence-based, preventive strategies. Lactation is an underrecognized, time-sensitive health behavior that improves cardiovascular outcomes across the life course.

Acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality worldwide. Sex- and gender-related differences in ACS persist and encompass risk profiles, clinical presentation, management, and outcomes.

Transcatheter aortic valve implantation (TAVI) has expanded from a treatment for inoperable and high-risk aortic stenosis to an established therapeutic option for selected patients at low surgical risk. This review focuses on the outcomes of major trials comparing TAVI to traditional surgical aortic valve replacement (SAVR), highlighting outcomes and potential complications when considering lifetime valve management as we move into the younger population. A literature search of PubMed using terms such as 'transcatheter aortic valve replacement' and 'low surgical risk' was used to identify relevant publications from within the last 10 years. Recent randomized trials and follow-up studies suggest that, in appropriately selected low-risk patients, TAVI and SAVR provide broadly comparable mid-term outcomes for cardiovascular mortality, stroke, and valve re-intervention. However, important differences remain. TAVI is consistently associated with lower rates of new-onset atrial fibrillation but higher rates of permanent pacemaker implantation and paravalvular aortic regurgitation. As TAVI moves into younger and asymptomatic populations, unresolved questions remain around valve durability, coronary access, redo strategies, and lifetime valve management, highlighting the central role of multidisciplinary heart-team assessment in selecting the optimal lifetime therapeutic strategy.

Revascularization post myocardial infarction is a complex interplay of patient and anatomical factors. There is a growing number of interventional tools providing both physiological and anatomical delineation of disease burden which can help determine the method and extent of revascularization. A tailored approach is required taking into consideration shared decision making, co-morbidities, and evolving treatment options.

Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation for atrial fibrillation (AF). Despite major technological advances, arrhythmia recurrence remains common because of pulmonary vein reconnection caused by non-durable lesions. Achieving durable PVI requires balancing effective lesion formation with the prevention of collateral injury.

Stress echocardiography (SE) is a widely used noninvasive imaging method to detect myocardial ischemia and assess prognosis in patients with suspected or established coronary artery disease (CAD). However, its results may challenge clinical interpretation and individualized management when technical performance is inadequate.

Takotsubo syndrome is an acute, transient ventricular dysfunction that frequently mimics acute coronary syndrome. Patients with cancer may be particularly vulnerable because malignancy-related stress and cancer therapies converge with cardiovascular susceptibility.

Ischemic heart disease remains a leading cause of morbidity and mortality worldwide despite advances in diagnosis, revascularization, and risk-factor control. Myocardial ischemia/reperfusion (I/R) injury (MIRI) is a multiphase process evolving over minutes to weeks, contributing to infarct expansion, microvascular obstruction, intramyocardial hemorrhage, and adverse ventricular remodeling. High-sensitivity cardiac troponins remain central to diagnosing myocardial necrosis but provide limited mechanistic insight into upstream MIRI processes.